Description du projet DEENESFRITPL Une thérapie en «cheval de Troie» pour les maladies inflammatoires de l’intestin Les maladies inflammatoires chroniques de l’intestin (MICI) se caractérisent par une inflammation chronique de celui-ci. Malgré leur prévalence croissante, l’étiologie précise demeure inconnue. Afin d’améliorer les résultats cliniques des patients atteints de MICI, le projet LeukoTheranostics, financé par l’UE, se propose de cibler les cellules immunitaires responsables de l’inflammation intestinale observée. Les chercheurs développeront des nanoparticules qui contiennent des molécules d’ARN interférent en tant que traitement thérapeutique et qui ciblent une protéine spécifique exprimée à la surface des leucocytes intestinaux. L’équipe utilisera des modèles murins de MICI pour suivre in vivo les nanoparticules et évaluer leur efficacité, ouvrant ainsi la voie à un traitement innovant des MICI de haute valeur clinique. Afficher les objectifs du projet Masquer les objectifs du projet Objectif "Inflammatory bowel diseases (IBD) is a group of chronic inflammatory conditions of the gastrointestinal tract, including Crohn’s disease (CD) and Ulcerative Colitis (UC) that can impact both the large and small bowel. IBD affects approximately 3.7 million Europeans and its peak onset is in persons of 15 to 30 years of age. IBD imposes a significant burden on Europe with over €3B in annual health care costs and over €3B in indirect cost. The prevalence of IBD is expected to increase by more than 40% over the next decade in many European countries. Therefore, to meet the needs of IBD patients in the European community, we must prepare for the evolving landscape of IBD care in the near future. Although its etiology remains unknown, unregulated immune cells are implicated in the pathogenesis of IBD. As many IBD patients are refractory to conventional medical treatments, there is an urgent need to develop novel therapeutic modalities in combination with real-time imaging in order to manage the disease. I will achieve this goal by generating a ""Trojan horse"" strategy of targeting activated leukocytes that home to the gut in IBD rodent models and reprogram their fate using RNA interference (RNAi) combined with molecular imaging. The primary objective of this proposal is to reprogram in vivo activated leukocytes involved in gut inflammation using advanced RNAi-based therapeutics combined with molecular imaging strategies as the first theranostic modality utilizing leukocytes. The following specific aims include: (i) To develop and characterize unique integrin-targeted nanoparticles (I-tsNPs) targeting a high-affinity (HA) conformation of a4b7 integrin expressed on gut leukocytes; (ii) To study I-tsNPs 3-dimensional (3-D) delivery in colitis models using microPET/CT imaging; (iii) To investigate efficacy and safety profiles using the HA I-tsNPs platform for IBD therapeutics and disease management that will lay the foundation for future clinical trials." Champ scientifique medical and health sciencesclinical medicinegastroenterologyinflammatory bowel diseasenatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesbasic medicineimmunologynatural sciencesbiological sciencesbiochemistrybiomoleculeslipidsengineering and technologynanotechnologynano-materials Programme(s) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Thème(s) ERC-CoG-2014 - ERC Consolidator Grant Appel à propositions ERC-2014-CoG Voir d’autres projets de cet appel Régime de financement ERC-COG - Consolidator Grant Institution d’accueil TEL AVIV UNIVERSITY Contribution nette de l'UE € 2 527 608,00 Adresse RAMAT AVIV 69978 Tel Aviv Israël Voir sur la carte Type d’activité Higher or Secondary Education Establishments Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 2 527 608,00 Bénéficiaires (2) Trier par ordre alphabétique Trier par contribution nette de l'UE Tout développer Tout réduire TEL AVIV UNIVERSITY Israël Contribution nette de l'UE € 2 527 608,00 Adresse RAMAT AVIV 69978 Tel Aviv Voir sur la carte Type d’activité Higher or Secondary Education Establishments Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 2 527 608,00 CHILDREN'S HOSPITAL CORPORATION États-Unis Contribution nette de l'UE € 175 517,00 Adresse LONGWOOD AVENUE 300 02115 Boston Voir sur la carte Type d’activité Research Organisations Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 175 517,00
